Whole genome sequencing for investigation of age-related chronic disease in HANDLS participants
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026R00166 in this department, oldest first.
- Sep 14, 2026 · this noticeCombined Synopsis/Solicitation
- Sep 22, 2026Combined Synopsis/SolicitationOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
Investigators in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study require whole genome sequencing (WGS) processing to expand our current research examining whether genetic variants contribute to age-related chronic diseases. Samples from HANDLS participants have been collected over 20 years and many are over 10 years old. A contract is required because the Government does not have available facilities or resources to perform this work consistent with other WGS performed on other HANDLS samples. The objective of this work is expanding our current research to e… (show all)
xamine health differences associated with age-related chronic diseases through whole genome sequencing to investigate the contributions of genomics to the burden of disease incidence, prevalence, morbidity, and mortality in populations within the United States. The long-term goal is to create a consistent dataset of whole genome sequencing to complement the longitudinal HANDLS behavior and health data. The contractor will deliver plates to the Government sufficient to run 600 samples, some of which have been stored for ten or more years. The contractor will perform whole genome sequencing, and specifically shall: Sequence libraries on the NovaSeq X-Plus platform with 25B-300 flow cells using 150 bp paired end runs and NovaSeq workflow-series 10B sequencing run confirm genomic DNA quantity and quality by performing DNA concentration measurements and volume checks Re-attempt sequencing in the case that DNA quality and quantity is sufficient, but sample fails sequencing-based quality control Examine agarose gels on all samples as an industry-standard method for screening DNA marker quality prepare PCR-free sequence libraries for all samples Sequence the libraries at a minimum of 30x coverage with 2�150 base pair runs Perform primary and secondary analysis of the sequencing data including but not limited to read alignment, variant calling, and quality control analyses Quality control checks will include confirming sex, identifying unexpected duplicates and relatedness, confirming relatedness, providing sample performance information and sample identity confirmation against the sequencing data, in addition to confirming coverage, contamination, mapped reads, and other general quality metrics. Alignment and variant calling will be performed with the DRAGEN Germline pipeline. After quality is confirmed, joint variant calling should be performed producing a multi-sample VCF file. Provide written summaries and documentation of the methods used to perform the whole genome sequencing pipeline Supply the whole genome sequencing data in a mutually acceptable electronic format that preserves study participants� confidentiality. Data delivered will include: per sample CRAMs per sample gVCFs per sample VCFs joint-called multi-sample VCF per sample structural variant and CNV calls QC report and data dictionary Sample manifest with flagged problems Following data delivery and upon request by the Government, the contractor shall provide attendance at Government laboratory staff meetings, and the contractor shall provide technical consultations as needed. The contractor will also ship overnight on dry ice any leftover samples on plates to the Biomedical Research Center in Baltimore, MD. Please refer to the attachments for complete details, specifications and relevant information.
Who won similar work
11 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) Q301.
Single-winner award sizes (11): middle half $70K to $297K, median $157K; range $27K to $35.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AZENTA US INC | 1 | $35.0M | Dec 2, 2024 |
| PSOMAGEN INC | 1 | $533K | Dec 31, 2024 |
| NEW YORK STEM CELL FOUNDATION INC | 1 | $362K | Sep 23, 2025 |
| BAYLOR MIRACA GENETICS LABORATORIES LLC | 1 | $232K | Sep 26, 2025 |
| THE BROAD INSTITUTE, INC | 1 | $215K | Sep 29, 2026 |
| NORGEN BIOTEK CORP | 1 | $157K | Sep 19, 2025 |
| KAISER FOUNDATION HOSPITALS 1 KAISER PLAZA 22ND FLOOR Oakland CA 94612 USA | 1 | $115K | Sep 22, 2025 |
| ProteinTech Group Inc | 1 | $90K | Sep 19, 2025 |
| GREENWOOD GENETIC CENTER INC | 1 | $49K | Sep 25, 2025 |
| HISTOSERV, INC | 1 | $29K | May 5, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Sep 29, 2026THE BROAD INSTITUTE, INC$215KWhole genome sequencing for investigation of age-related chronic disease in HANDLS participantsNo listed company matched (Materiality N/A)
- Sep 26, 2025BAYLOR MIRACA GENETICS LABORATORIES LLC$232KQ--Clinical TestingNo listed company matched (Materiality N/A)
- Sep 25, 2025GREENWOOD GENETIC CENTER INC$49KQ--Genetic Testing with Greenwood Genetic Center IncNo listed company matched (Materiality N/A)
- Sep 23, 2025NEW YORK STEM CELL FOUNDATION INC$362KQ--iPSC Generation and Beta Cell DifferentiationNo listed company matched (Materiality N/A)
- Sep 22, 2025KAISER FOUNDATION HOSPITALS 1 KAISER PLAZA 22ND FLOOR Oakland CA 94612 USA$115KQ--Adherence with continuous positive airwayNo listed company matched (Materiality N/A)
- Sep 19, 2025NORGEN BIOTEK CORP$157KQ--Small RNA characterization of urinary exosomesNo listed company matched (Materiality N/A)
- Sep 19, 2025ProteinTech Group Inc$90KCRO Services for Single-Cell Multiomics ProfilingNo listed company matched (Materiality N/A)
- Jul 24, 2025ADVANCED CELL DIAGNOSTICS, INC.$27KQ--RNAscope In-House AssayMateriality: <0.01% of $TECH revenue (Low) SEC
- May 5, 2025HISTOSERV, INC$29KSignatures of aging outcomesNo listed company matched (Materiality N/A)
- Dec 31, 2024PSOMAGEN INC$533KLong read sequencing servicesNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 5 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.